For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Restructuring charges | - | 4,527 | ||
| Research and development | 1,247 | 10,537 | ||
| General and administrative | 1,919 | 1,817 | ||
| Total operating expenses | 3,166 | 16,881 | ||
| Loss from operations | -3,166 | -16,881 | ||
| Interest income | 123 | 246 | ||
| Interest expense | 10 | 7 | ||
| Australian research and development incentives | -56 | 1 | ||
| Foreign currency gain (loss) | 8 | -2 | ||
| Loss before income taxes | -3,101 | - | ||
| Provision for income taxes | 202 | - | ||
| Net loss | -3,303 | -16,643 | ||
| Net loss attributable to common stockholders | -3,303 | -16,643 | ||
| Basic EPS | -0.08 | -0.4 | ||
| Diluted EPS | -0.08 | -0.4 | ||
| Basic Average Shares | 41,444,979 | 41,444,979 | ||
| Diluted Average Shares | 41,444,979 | 41,444,979 | ||
LEAP THERAPEUTICS, INC. (LPTX)
LEAP THERAPEUTICS, INC. (LPTX)